Status: retired, Not sufficiently defined by necessary conditions definition status. Date: 01-Apr 2018. Module: SNOMED CT United Kingdom drug extension module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 71112901000001116 | Ceftaroline fosamil acetic acid solvate monohydrate (substance) | en | Fully specified name | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| 71113001000001113 | Ceftaroline fosamil acetic acid solvate monohydrate | en | Synonym | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Ceftaroline fosamil acetic acid solvate monohydrate | Is a | Substance with cephalosporin structure and antibacterial mechanism of action | false | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Ceftaroline fosamil 600mg powder for solution for infusion vials | Has specific active ingredient | False | Ceftaroline fosamil acetic acid solvate monohydrate | Inferred relationship | Existential restriction modifier | |
| Zinforo 600mg powder for concentrate for solution for infusion vials (AstraZeneca UK Ltd) | Has specific active ingredient | False | Ceftaroline fosamil acetic acid solvate monohydrate | Inferred relationship | Existential restriction modifier | |
| Ceftaroline fosamil 600mg powder for solution for infusion vials 10 vial | Has specific active ingredient | False | Ceftaroline fosamil acetic acid solvate monohydrate | Inferred relationship | Existential restriction modifier | |
| Zinforo 600mg powder for concentrate for solution for infusion vials (AstraZeneca UK Ltd) 10 vial | Has specific active ingredient | False | Ceftaroline fosamil acetic acid solvate monohydrate | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets
FHIR